The 8th International Symposium on Targeted Anticancer Therapies (TAT 2010) covered a broad range of promising new drug targets and drugs affecting these targets. TAT 2010 provided overviews - in keynotes and expert reviews - of drug development by molecular target but also many presentations of recent results of early-phase clinical studies with particular targeted agents. The TAT 2010 program counted more speakers (53) than any previous TAT meeting. They presented excellent lectures covering dozens of molecular targets. Two specific molecular targets were discussed extensively in separate sessions: the insulin-like growth factor type 1 receptor (IGF-1R) and inhibitors of DNA damage repair enzymes, in particular PARP.

A traditional element of the TAT program is the NDDO Honorary Award Lecture. This year, the Lecture was awarded to Dr. Axel Ullrich of the Max Planck Institute in Martinsried near Munich. His work in the past decades has been of crucial importance for the successful development of two targeted agents for cancer: trastuzumab (Herceptin) and sunitinib (Sutent). He founded the biotech company Sugen, where sunitinib was initially discovered and developed before it was taken over by Pfizer. The title of the NDDO Honorary Award Lecture 2010 was "Genetic determinants as basis for targeted cancer therapies: From trastuzumab to sunitinib and further ..."

TAT 2010 was held in Bethesda, MD, and was the second congress in this successful series held in the United States since the U.S. National Cancer Institute (NCI) joined the NDDO Education Foundation as a partner in the series of annual TAT congresses.

If you wish to view TAT 2010 presentations (PDF) and/or abstracts of TAT 2010, just click the banners on the right-hand side of this webpage. The abstract banner will take you to the website of Annals of Oncology, the official journal of ESMO. Abstracts of all TAT meeings held since 2005 have been published in Annals of Oncology